Valeris Reports Impressive Growth and Milestones
Valeris, a fully integrated life sciences commercialization partner, has announced impressive results for the fiscal year 2025. With significant growth and notable integration achievements, the company has solidified its role as a leading partner in US Market Access and Patient Services, aiding biopharma companies from pre-launch to long-term commercialization.
CEO Rob Truckenmiller expressed, "Valeris was designed to tackle one of the major challenges in US healthcare: ensuring patients can access and stay on therapy amidst the complexities of the system. Our integrated model has proven effective in 2025, as we've demonstrated strong financial performance, gained new partner trust, and showed that a unified approach in market access strategy, patient services, technology, and insights benefits both patients and brands. Our goal is to lead in US Market Access throughout the product lifecycle. As we advance into 2026, we aim to enhance our capabilities, strengthen our relationships, and drive tangible results for the biopharma brands we serve."
Several key developments from Valeris in 2025 are worth highlighting:
Significant Merger and Financial Success
Successful Merger of Mercalis and PharmaCord
- The announcement of the merger between Mercalis and PharmaCord took place on March 12. With support from private equity firms Permira and Odyssey Investment Partners, the newly formed entity was launched as Valeris on May 27. This merger came about in response to the increasing intricacies of patient access and commercialization challenges, combining patient support expertise and advanced technology within a single platform.
- Valeris had an extraordinary first year, outperforming financial and new business objectives. Patient Support Services were pivotal in this success, bringing on over 20 new partners — a testament to growing market trust and demand. Every business line within Valeris exhibited robust growth, underscoring the comprehensive strength and scalability of its offerings, which positions the company for continued success in 2026.
Expanding Leadership Team
Key Executive Appointments
- Valeris has enhanced its Executive Leadership team by hiring three experienced C-Suite Executives. In July, Jodi Dickinson was appointed Chief People Officer (CPO) and Peter Formisano joined as Chief Operating Officer (COO). Dickinson brings nearly three decades of HR leadership to strengthen Valeris's people-focused approach, while Formisano's passion for AI-driven innovation will enhance Valeris's operational excellence.
- In September, Manish Goel became the Chief Technology Officer (CTO). With a background at companies like IQVIA and Oracle, Goel will drive global technology initiatives aimed at innovation and improving patient outcomes.
Innovations Driving Growth
Strategic Investments for Future Success
- Valeris is committed to a forward-looking product strategy. The company made key investments to scale its platform and drive long-term growth, focusing on enhancing patient and provider experiences through various new and innovative product initiatives.
- Demonstrating its commitment to security, Valeris successfully reacquired the prestigious ISO/IEC 27001 accreditation, confirming its leadership in data security management.
Diverse Service Offerings Yielding Results
Market Access & Advisory Services Achieve Record Performance
- Valeris's Market Access & Advisory Services saw remarkable success, complemented by partnerships and engagements that have bolstered its market presence. The services experienced more than a 20% year-over-year increase in revenue, showcasing its ability to secure client trust and continuity.
Looking Ahead to the Future
As Valeris ventures into 2026, the company is poised to focus on growth beyond integration, continuing its leadership in US Market Access and Patient Services. Investments will further enhance technology innovation and responsible AI applications aimed at streamlining patient support.
Truckenmiller stated, "Integration was just the beginning — scaling growth is our directive for 2026. We're committed to leveraging technology and AI to enhance our market access strategies and help partners effectively reach patients with more precision and impact. Our success metrics are tied to outcomes for patients, brands, and the healthcare system."
About Valeris
Valeris is an integrated life sciences commercialization partner offering comprehensive solutions that span the healthcare value chain. The organization is dedicated to enhancing patient experiences, ensuring access to critical medications. With deep industry knowledge and a skilled workforce, Valeris provides data and strategic insights, patient support, and provider engagement tools to facilitate the successful commercialization of new life science products. The company operates with over 500 life sciences partners, supporting millions of patients and is headquartered across multiple locations.
Frequently Asked Questions
What does Valeris specialize in?
Valeris specializes in life sciences commercialization, focusing on market access, patient services, and enhancing patient experiences in healthcare.
When was Valeris launched?
Valeris was launched on May 27, following the merger of Mercalis and PharmaCord.
What key hires did Valeris make in 2025?
In 2025, Valeris appointed Jodi Dickinson as CPO, Peter Formisano as COO, and Manish Goel as CTO.
What accreditation did Valeris achieve?
Valeris achieved the ISO/IEC 27001 accreditation for its Information Security Management System, which it has maintained since 2018.
What are Valeris’s future plans?
Valeris aims to expand its market access capabilities, continue innovative technology investments, and enhance patient support services in the coming years.
